MiR-124 regulated genes and pathways as targets for therapeutic intervention

• US 8,071,562 B2
• Filed: 12/01/2008
• Issued: 12/06/2011
• Est. Priority Date: 12/01/2007
• Status: Expired due to Fees

• Current Assignee: Mirna Therapeutics, Inc. (Synlogic, Inc.)
• Original Assignee: Mirna Therapeutics, Inc. (Synlogic, Inc.)
• Inventors: Bader, Andreas G., Wiggins, Jason F., Patrawala, Lubna, Kelnar, Kevin, Byrom, Mike, Brown, David
• Primary Examiner(s): WHITEMAN, BRIAN A
• Application Number:
  US12/325,917
• Publication Number:
  US 20090192111A1
• Time in Patent Office: 1,100 Days
• Field of Search: 514/44
• US Class Current: 514/44.A
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs
• CPC Class Codes: C12N 2330/10 naturally occurring

Abstract

The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.

Claims

1. A method of inhibiting proliferation of a prostate or liver cancer cell comprising administering to a subject having a prostate cancer or liver cancer cell an isolated nucleic acid comprising a miR-124 nucleic acid sequence in combination with an isolated nucleic acid comprising a miR-34a, let-7b, let-7c, or let-7g nucleic acid sequence in an amount sufficient to inhibit proliferation of the prostate or liver cancer cell.

2. The method of claim 1, wherein the prostate carcinoma is associated with detectable prostate-specific antigen (PSA).

3. The method of claim 1, wherein the prostate carcinoma is androgen independent.

4. The method of claim 1, wherein the liver carcinoma is hepatoma, hepatocarcinoma or an hepatic adenocarcinoma.

5. The method of claim 1, wherein the liver carcinoma is hepatoblastoma, or a cholangiocarcinoma.

6. The method of claim 1, wherein the isolated miR-124, miR-34a, let-7b, let-7c, or let-7g nucleic acid is a recombinant nucleic acid.

7. The method of claim 1, wherein the miR-124, miR-34a, let-7b, let-7c, or let-7g nucleic acid is a synthetic nucleic acid.

8. The method of claim 1, wherein the nucleic acid is administered enterally or parenterally.

9. The method of claim 1, wherein the nucleic acid is comprised in a pharmaceutical formulation.

10. The method of claim 9, wherein the pharmaceutical formulation is a lipid composition or a nanoparticle composition.

11. The method of claim 9, wherein the pharmaceutical formulation consists of biocompatible and biodegradable molecules.